Currently, there are 1.15B common shares owned by the public and among those 1.15B shares have been available to trade.
The company’s stock has a 5-day price change of -0.94% and 1.94% over the past three months. TEVA shares are trading -23.87% year to date (YTD), with the 12-month market performance up to 0.12% higher. It has a 12-month low price of $12.47 and touched a high of $22.80 over the same period. TEVA has an average intraday trading volume of 12.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.83%, 7.27%, and -4.34% respectively.
Institutional ownership of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) shares accounts for 62.93% of the company’s 1.15B shares outstanding.
It has a market capitalization of $19.23B and a beta (3y monthly) value of 0.63. The earnings-per-share (ttm) stands at -$1.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.31% over the week and 3.71% over the month.
Analysts forecast that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will achieve an EPS of 0.63 for the current quarter, 0.72 for the next quarter and 2.76 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.59 while analysts give the company a high EPS estimate of 0.59. Comparatively, EPS for the current quarter was 0.61 a year ago. Earnings per share for the fiscal year are expected to increase by 1.89%, and 7.54% over the next financial year. EPS should grow at an annualized rate of 7.00% over the next five years, compared to -9.62% over the past 5-year period.
Looking at the support for the TEVA, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on May 28, 2025, with the firm’s price target at $25. JP Morgan coverage for the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock in a research note released on May 12, 2025 offered a Overweight rating with a price target of $23. Argus was of a view on July 10, 2024 that the stock is Buy, while JP Morgan gave the stock Neutral rating on March 08, 2024, issuing a price target of $14. Piper Sandler on their part issued Overweight rating on February 12, 2024.
